JP2020510074A5 - - Google Patents
Info
- Publication number
- JP2020510074A5 JP2020510074A5 JP2019550784A JP2019550784A JP2020510074A5 JP 2020510074 A5 JP2020510074 A5 JP 2020510074A5 JP 2019550784 A JP2019550784 A JP 2019550784A JP 2019550784 A JP2019550784 A JP 2019550784A JP 2020510074 A5 JP2020510074 A5 JP 2020510074A5
- Authority
- JP
- Japan
- Prior art keywords
- car polypeptide
- cells
- polypeptide according
- car
- cell
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022102796A JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472275P | 2017-03-16 | 2017-03-16 | |
| US62/472,275 | 2017-03-16 | ||
| US201762580243P | 2017-11-01 | 2017-11-01 | |
| US62/580,243 | 2017-11-01 | ||
| US201762584060P | 2017-11-09 | 2017-11-09 | |
| US62/584,060 | 2017-11-09 | ||
| USPCT/US2018/013213 | 2018-01-10 | ||
| PCT/US2018/013213 WO2018132506A1 (en) | 2017-01-10 | 2018-01-10 | Chimeric antigen receptors based on alternative signal 1 domains |
| PCT/US2018/022974 WO2018170458A1 (en) | 2017-03-16 | 2018-03-16 | Chimeric antigen receptors targeting cd37 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102796A Division JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020510074A JP2020510074A (ja) | 2020-04-02 |
| JP2020510074A5 true JP2020510074A5 (https=) | 2022-07-12 |
| JPWO2018170458A5 JPWO2018170458A5 (https=) | 2022-07-12 |
| JP7254710B2 JP7254710B2 (ja) | 2023-04-10 |
Family
ID=63522693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550784A Active JP7254710B2 (ja) | 2017-03-16 | 2018-03-16 | Ｃｄ３７を標的にするキメラ抗原受容体 |
| JP2022102796A Pending JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102796A Pending JP2022130557A (ja) | 2017-03-16 | 2022-06-27 | Ｃｄ３７を標的にするキメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11352434B2 (https=) |
| EP (1) | EP3595721B1 (https=) |
| JP (2) | JP7254710B2 (https=) |
| CN (2) | CN118599009A (https=) |
| AU (2) | AU2018236450A1 (https=) |
| CA (1) | CA3056115A1 (https=) |
| WO (1) | WO2018170458A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| AU2018236450A1 (en) | 2017-03-16 | 2019-10-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2023133488A1 (en) * | 2022-01-06 | 2023-07-13 | The General Hospital Corporation | Methods of cell ablation |
| WO2024103049A1 (en) * | 2022-11-11 | 2024-05-16 | The United States Government As Represented By The Department Of Veterans Affairs | Cd33 specific exosomes and uses thereof |
| CN119080947B (zh) * | 2024-08-30 | 2025-06-27 | 黄山永生部落干细胞科技有限公司 | 一种靶向cd37的嵌合抗原受体（car）及其抗癌的用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| EP2365003A1 (en) * | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| US20180133252A9 (en) * | 2014-09-09 | 2018-05-17 | Unum Therapeutics Inc. | Chimeric receptors and uses thereof in immune therapy |
| WO2016054520A2 (en) | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| SG10202108116SA (en) * | 2015-06-08 | 2021-08-30 | Debiopharm International S A | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
| GB201514874D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
| GB201600328D0 (en) | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| AU2018236450A1 (en) | 2017-03-16 | 2019-10-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 |
| WO2019246546A1 (en) | 2018-06-22 | 2019-12-26 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
-
2018
- 2018-03-16 AU AU2018236450A patent/AU2018236450A1/en not_active Abandoned
- 2018-03-16 CN CN202410332918.XA patent/CN118599009A/zh active Pending
- 2018-03-16 US US16/493,142 patent/US11352434B2/en active Active
- 2018-03-16 CA CA3056115A patent/CA3056115A1/en active Pending
- 2018-03-16 JP JP2019550784A patent/JP7254710B2/ja active Active
- 2018-03-16 WO PCT/US2018/022974 patent/WO2018170458A1/en not_active Ceased
- 2018-03-16 EP EP18768250.5A patent/EP3595721B1/en active Active
- 2018-03-16 CN CN201880022534.0A patent/CN110461363B/zh active Active
-
2022
- 2022-05-10 US US17/741,166 patent/US20230167190A1/en active Pending
- 2022-06-27 JP JP2022102796A patent/JP2022130557A/ja active Pending
-
2025
- 2025-03-20 AU AU2025202029A patent/AU2025202029B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023278069B2 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| US20230250150A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| JP2020510074A5 (https=) | ||
| White et al. | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies | |
| JP2023130380A (ja) | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 | |
| Chu et al. | Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells | |
| AU2018207300B2 (en) | T cells expressing a chimeric antigen receptor | |
| AU2014337195B2 (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| Lee et al. | Novel antibodies targeting immune regulatory checkpoints for cancer therapy | |
| CN111971053A (zh) | 靶向肿瘤微环境的嵌合抗原受体 | |
| US20230167190A1 (en) | Chimeric antigen receptors targeting cd37 | |
| CA3063169A1 (en) | T cells expressing a chimeric antigen receptor | |
| US20250186496A1 (en) | Methods and compositions for controlling t cell activation | |
| JP2022514815A (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| JPWO2018170458A5 (https=) | ||
| WO2025117851A1 (en) | Meso-fap with adam17 inhibitor or itk inhibitor | |
| CA3204050A1 (en) | Anti-cd72 nanobodies for immunotherapy |